ENANTA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.37 USD | -0.88% |
|
-7.13% | +31.46% |
| Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
| Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,182 | 918.9 | 1,148 | 1,075 | 235.2 | 261.7 | - | - |
| Enterprise Value (EV) 1 | 848.9 | 918.9 | 1,148 | 1,075 | 235.2 | 261.7 | 261.7 | 261.7 |
| P/E ratio | 27.2 x | -25.3 x | -14.5 x | -8.78 x | -1.75 x | -2.37 x | -2.51 x | -2.88 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.76 x | 7.5 x | 11.8 x | 12.5 x | 2.97 x | 3.8 x | 3.57 x | 3.61 x |
| EV / Revenue | 5.76 x | 7.5 x | 11.8 x | 12.5 x | 2.97 x | 3.8 x | 3.57 x | 3.61 x |
| EV / EBITDA | 20 x | -49.9 x | -13.5 x | -11.4 x | -2.21 x | -2.36 x | -2.06 x | - |
| EV / FCF | 17.9 x | 163 x | -16.2 x | -12.4 x | -2.1 x | -2.12 x | -2.09 x | -1.38 x |
| FCF Yield | 5.58% | 0.61% | -6.16% | -8.08% | -47.7% | -47.2% | -47.8% | -72.6% |
| Price to Book | 2.56 x | 2 x | 2.88 x | 3.33 x | 1.09 x | 1.44 x | 1.44 x | 1.85 x |
| Nbr of stocks (in thousands) | 19,682 | 20,072 | 20,215 | 20,725 | 21,055 | 21,156 | - | - |
| Reference price 2 | 60.08 | 45.78 | 56.81 | 51.87 | 11.17 | 12.37 | 12.37 | 12.37 |
| Announcement Date | 11/21/19 | 11/23/20 | 11/22/21 | 11/21/22 | 11/20/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 205.2 | 122.5 | 97.07 | 86.16 | 79.2 | 68.81 | 73.31 | 72.55 |
| EBITDA 1 | 59.22 | -18.42 | -85.25 | -93.9 | -106.6 | -111 | -127 | - |
| EBIT 1 | 36.74 | -41.64 | -109.6 | -123.8 | -137.2 | -113.3 | -114.8 | -118.6 |
| Operating Margin | 17.9% | -34% | -112.88% | -143.74% | -173.23% | -164.68% | -156.59% | -163.43% |
| Earnings before Tax (EBT) 1 | 45.56 | -35.02 | -107.6 | -122.2 | -131 | -117.3 | -128.1 | -123.8 |
| Net income 1 | 46.38 | -36.17 | -79 | -121.8 | -133.8 | -110.1 | -116.2 | -118.1 |
| Net margin | 22.6% | -29.53% | -81.38% | -141.31% | -168.95% | -159.97% | -158.58% | -162.74% |
| EPS 2 | 2.210 | -1.810 | -3.920 | -5.910 | -6.380 | -5.212 | -4.937 | -4.302 |
| Free Cash Flow 1 | 66 | 5.643 | -70.75 | -86.91 | -112.2 | -123.5 | -125 | -190 |
| FCF margin | 32.16% | 4.61% | -72.88% | -100.87% | -141.67% | -179.47% | -170.51% | -261.89% |
| FCF Conversion (EBITDA) | 111.45% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 142.3% | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/21/19 | 11/23/20 | 11/22/21 | 11/21/22 | 11/20/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.58 | 27.65 | 18.72 | 19.48 | 20.32 | 23.58 | 17.8 | 18.89 | 18.93 | 18 | 16.21 | 16.77 | 17.19 | 19.9 | 15.46 |
| EBITDA 1 | -27.57 | - | - | - | - | - | - | - | - | - | -32 | -26 | -21 | - | - |
| EBIT 1 | -33.73 | -30.41 | -33.85 | -32.54 | -27.05 | -30.01 | -39.45 | -36.71 | -31.03 | -34.89 | -29.24 | -26.55 | -22.87 | -34.52 | -37.96 |
| Operating Margin | -143.06% | -109.99% | -180.85% | -167.05% | -133.13% | -127.25% | -221.7% | -194.33% | -163.9% | -193.78% | -180.42% | -158.36% | -133.04% | -173.47% | -245.43% |
| Earnings before Tax (EBT) 1 | -33.39 | -30.15 | -33.59 | -32.15 | -26.33 | -29.02 | -37.61 | -34.84 | -29.52 | -34.03 | -28.34 | -27.38 | -25.21 | -34.54 | -36.51 |
| Net income 1 | -24.6 | -30.12 | -33.59 | -31.7 | -26.35 | -28.99 | -37.66 | -39.06 | -28.11 | -33.41 | -27.15 | -26.78 | -24.68 | -30.22 | -35.89 |
| Net margin | -104.34% | -108.92% | -179.48% | -162.74% | -129.68% | -122.9% | -211.62% | -206.78% | -148.46% | -185.56% | -167.52% | -159.68% | -143.62% | -151.9% | -232.06% |
| EPS 2 | -1.220 | -1.480 | -1.630 | -1.530 | -1.270 | -1.390 | -1.790 | -1.860 | -1.330 | -1.580 | -1.299 | -1.220 | -1.027 | -1.440 | -1.700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/22/21 | 2/8/22 | 5/9/22 | 8/8/22 | 11/21/22 | 2/7/23 | 5/8/23 | 8/7/23 | 11/20/23 | 2/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 334 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 66 | 5.64 | -70.7 | -86.9 | -112 | -124 | -125 | -190 |
| ROE (net income / shareholders' equity) | 10.8% | -7.88% | -18.5% | -33.8% | -49.7% | -57.8% | -62.5% | -64.1% |
| ROA (Net income/ Total Assets) | 10.3% | -7.41% | -17.1% | -29.9% | -31.9% | -28.7% | -37.3% | -44.6% |
| Assets 1 | 452 | 488 | 462.5 | 407.1 | 418.8 | 383.6 | 311.7 | 264.6 |
| Book Value Per Share 2 | 23.50 | 22.80 | 19.70 | 15.60 | 10.30 | 8.580 | 8.570 | 6.700 |
| Cash Flow per Share | 3.410 | - | - | - | - | - | - | - |
| Capex 1 | 5.42 | 1.45 | 0.75 | 2.13 | 9.06 | 9 | 9 | - |
| Capex / Sales | 2.64% | 1.18% | 0.77% | 2.47% | 11.44% | 13.08% | 12.28% | - |
| Announcement Date | 11/21/19 | 11/23/20 | 11/22/21 | 11/21/22 | 11/20/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
12.37
USD
Average target price
20.88
USD
Spread / Average Target
+68.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.46% | 262M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ENTA Stock
- Financials Enanta Pharmaceuticals, Inc.
